Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was ...
Altimmune (ALT) stock is in focus as the company announces data from a mid-stage trial for its MASH therapy pemvidutide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback